• BI drug gets orphan status for MDS pharmatimes
    March 13, 2017
    Boehringer Ingelheim has bagged US orphan drug designation for its anti-CD33 monoclonal antibody BI 836858 for the treatment of myelodysplastic syndromes (MDS).
PharmaSources Customer Service